Journal
BMJ-BRITISH MEDICAL JOURNAL
Volume 379, Issue -, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bmj-2022-073070
Keywords
-
Categories
Ask authors/readers for more resources
This study estimated the effectiveness of a two dose vaccine schedule against SARS-CoV-2 infection, COVID-19 related death, and short-term waning of immunity in children and adolescents during periods of delta and omicron variant predominance in Argentina. The results showed that vaccine effectiveness in preventing SARS-CoV-2 infection declined over time, especially during the omicron period. However, the vaccine remained effective in preventing death related to SARS-CoV-2 infection.
Objective To estimate the effectiveness of a two dose vaccine schedule (mRNA-1273, BNT162b2, and BBIBP-CorV) against SARS-CoV-2 infection and covid-19 related death and short term waning of immunity in children (3-11 years old) and adolescents (12-17 years old) during periods of delta and omicron variant predominance in Argentina. Design Test negative, case-control study. Setting Database of the National Surveillance System and the Nominalized Federal Vaccination Registry of Argentina. Participants 844 460 chi hildren and adolescents without previous SARS-CoV-2 infection eligible to receive primary vaccination schedule who were tested for SARS-CoV-2 by polymerase chain reaction or rapid antigen test from September 2021 to April 2022. After matching with their corresponding controls, 139 321 (60.3%) of 231 181 cases remained for analysis. Exposures Two dose mRNA-1273, BNT162b2, and BBIBP-CorV vaccination schedule. Main outcome measures SARS-CoV-2 infection and covid-19 related death. Conditional logistic regression was used to estimate the odds of SARS-CoV-2 infection among two dose vaccinated and unvaccinated participants. Vaccine effectiveness was estimated as (1-odds ratio)x100%. Results Estimated vaccine effectiveness against SARS-CoV-2 infection was 61.2% (95% confidence interval 56.4% to 65.5%) in children and 66.8% (63.9% to 69.5%) in adolescents during the delta dominant period and 15.9% (13.2% to 18.6%) and 26.0% (23.2% to 28.8%), respectively, when omicron was dominant. Vaccine effectiveness declined over time, especially during the omicron period, from 37.6% (34.2% to 40.8%) at 15-30 days after vaccination to 2.0% (1.8% to 5.6%) after =60 days in children and from 55.8% (52.4% to 59.0%) to 12.4% (8.6% to 16.1%) in adolescents. Vaccine effectiveness against death related to SARSCoV-2 infection during omicron predominance was 66.9% (6.4% to 89.8%) in children and 97.6% (81.0% to 99.7%) in adolescents. Conclusions Vaccine effectiveness in preventing mortality remained high in children and adolescents regardless of the circulating variant. Vaccine effectiveness in preventing SARS-CoV-2 infection in the short term after vaccination was lower during omicron predominance and decreasing sharply over time.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available